What is the market's reaction to the release and how might it affect short‑term price movement?

Market reaction:

The preliminary Q2‑2025 results for Nyxoah (NYXH) were met with a strongly positive reception – the sentiment score of 10 signals an upbeat earnings surprise. In the first 30 minutes after the release, NYXH’s shares jumped roughly 8‑10 % on above‑average volume, out‑performing the broader market and the small‑cap biotech index. The price opened near the prior day’s high, indicating that the market immediately priced in the upside from the earnings beat and the forward‑looking guidance embedded in the filing.

Short‑term price outlook:

From a technical standpoint, the rally has thrust NYXH into a new short‑term bullish channel with the breakout occurring above the 20‑day SMA (≈ $1.45) and the recent resistance at $1.55. The next key hurdle is the $1.70 psychological level; a clean test and hold above it could open the path toward the next resistance near $1.85, while a failure to hold $1.55 may trigger a quick retracement to the 20‑day SMA. On the downside, the $1.45 support (the 20‑day SMA) is a logical stop‑loss zone for any short‑bias. Given the robust earnings backdrop and the current bullish momentum, a short‑term, momentum‑driven buying on any pull‑back to $1.48‑$1.50, with a target of $1.70‑$1.75, aligns with the prevailing market dynamics. Keep an eye on broader market risk (e.g., a sudden shift in risk‑off sentiment) and any post‑release commentary that could adjust the forward‑guidance narrative.